Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 7/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27792889 | 0.82 | IDO1 (0.69) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL828720 | 0.82 | IDO1 (0.62) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL786628 | 0.82 | IDO1 (0.44) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL9576160 | 0.82 | ALOX5 (0.66) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL29500198 | 0.80 | IDO1 (0.66) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL622754 | 0.80 | IDO1 (0.66) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL22284783 | 0.80 | IDO1 (0.61) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL11725667 | 0.80 | IDO1 (0.61) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| SCHEMBL2477378 | 0.79 | TLR2 (0.56) | IDO1ALOX5PTGS2MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL16037890 | 0.79 | IDO1 (0.65) | IDO1ALOX5PTGS2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | disclosed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | disclosed |
| EP-3233861-B1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL) PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2019-04-10 | — | — | EP | disclosed |
| US-10093675-B2 | 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-10-09 | — | — | US | disclosed |
| US-20170362236-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2017-12-21 | — | — | US | disclosed |
| EP-3233861-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | Ustav Experimentalni Botaniky Av CR, V.V.I. (CZ) | 2017-10-25 | — | — | EP | disclosed |
| EP-1575973-B1 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2017-08-23 | — | — | EP | disclosed |
| EP-2438068-B1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2017-03-01 | — | — | EP | disclosed |
| EP-2755977-B1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE | Univerzita Palackého v Olomouci (CZ) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016095880-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2016-06-23 | — | — | WO | disclosed |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | disclosed |
| EP-1475094-A1 | Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2004-11-10 | — | — | EP | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
| US-4196291-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1980-04-01 | — | — | US | disclosed |
| US-4141978-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-02-27 | — | — | US | disclosed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4001411-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ADAR, ADORA2A, AMPD2 | IDO1 222/4885ALOX5 1725/4885PTGS2 3596/4885 |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | IDO1 2607/4885ALOX5 1653/4885PTGS2 1998/4885 |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ATIC, UMPS, CCNB1 | IDO1 233/4885ALOX5 2713/4885PTGS2 2560/4885 |
| US-20170362236-A1 | 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS | PNP, UNG, NUDT1 | IDO1 999/4885ALOX5 439/4885PTGS2 300/4885 |
| US-10093675-B2 | 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications | PNP, UNG, NUDT1 | IDO1 999/4885ALOX5 439/4885PTGS2 300/4885 |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | IDO1 165/4885ALOX5 742/4885PTGS2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.